CliffBio
biologic

Gamifant

emapalumab-lzsg

Loss of exclusivityNovember 2030projected — 12-year biologic exclusivity estimate
CompanySwedish Orphan Biovitrum AB (publ)

Drug detail

Brand nameGamifant
Active ingredientemapalumab-lzsg
Strength10MG/2ML (5MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalNovember 2018
Marketing statusRx

More from Swedish Orphan Biovitrum AB (publ)

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Gamifant patent cliff — loss of exclusivity November 2030 | CliffBio